Drug Profile
Research programme: MRSA therapeutics and vaccines - Immunartis
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Immunartis
- Class Antibodies; Bacterial vaccines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Methicillin-resistant Staphylococcus aureus infections in China (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in China
- 29 Jul 2016 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in China (unspecified route)